Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ARCA biopharma, Inc. (ABIO : NSDQ)
 
 • Company Description   
ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products. The Company's business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

Number of Employees: 19

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.29 Daily Weekly Monthly
20 Day Moving Average: 112,093 shares
Shares Outstanding: 14.41 (millions)
Market Capitalization: $33.00 (millions)
Beta: 2.20
52 Week High: $3.90
52 Week Low: $1.71
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.29% 8.16%
12 Week 20.53% 30.78%
Year To Date 6.51% 26.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10170 CHURCH RANCH WAY SUITE 100
-
WESTMINSTER,CO 80021
USA
ph: 720-940-2200
fax: 720-208-9261
derek.cole@arcabio.com http://www.arcabio.com
 
 • General Corporate Information   
Officers
Michael R. Bristow - Chief Executive Officer. President and Director
C. Jeffrey Dekker - Chief Financial Officer
Linda Grais - Director
Raymond Woosley - Director
Robert Conway - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00211Y506
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 14.41
Most Recent Split Date: 4.00 (0.06:1)
Beta: 2.20
Market Capitalization: $33.00 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.69
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 30.30%
vs. Previous Quarter: 42.50%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -34.12
12/31/21 - -32.92
09/30/21 - -32.61
ROA
03/31/22 - -31.96
12/31/21 - -30.96
09/30/21 - -30.63
Current Ratio
03/31/22 - 18.59
12/31/21 - 15.56
09/30/21 - 18.75
Quick Ratio
03/31/22 - 18.59
12/31/21 - 15.56
09/30/21 - 18.75
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 3.33
12/31/21 - 3.54
09/30/21 - 3.93
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©